Search Results
10
Everything
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
February 27, 2025 09:45 ET
|
BioRestorative Therapies, Inc
– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company’s advanced clinical pipeline...
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update
February 26, 2025 20:15 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused...
BioRestorative to Provide a Positive FDA Update on Clinical Pipeline
February 25, 2025 08:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused...
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
February 20, 2025 08:30 ET
|
BioRestorative Therapies, Inc
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date – – May also...
BRTX-100 Front and Center at ORS 2025
February 10, 2025 07:00 ET
|
BioRestorative Therapies, Inc
– New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health” presentation – – Among other positive preliminary data...
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
November 13, 2024 07:00 ET
|
BioRestorative Therapies, Inc
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in...
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
November 06, 2024 07:00 ET
|
BioRestorative Therapies, Inc
– New blinded preliminary safety and efficacy data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in podium presentation on November 13, 2024 – – Data will be on a significantly...
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
November 05, 2024 07:10 ET
|
BioRestorative Therapies, Inc
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research – MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative...
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
October 31, 2024 07:00 ET
|
BioRestorative Therapies, Inc
– Further expands already formidable intellectual property estate the Company has been building for its novel ThermoStem® technology platform – MELVILLE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) --...